Beta counters

Information:SAR-20347 is a potent inhibitor ofTYK2,JAK1,JAK2andJAK3with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediatedIL-12andIFN-αsignaling.Targets:IL-12 : IFN-α : TYK2 (Cell-free assay): JAK1

Information:SAR-20347 is a potent inhibitor ofTYK2,JAK1,JAK2andJAK3with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediatedIL-12andIFN-αsignaling.Targets:IL-12 : IFN-α : TYK2 (Cell-free assay): JAK1

Information:SAR-20347 is a potent inhibitor ofTYK2,JAK1,JAK2andJAK3with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediatedIL-12andIFN-αsignaling.Targets:IL-12 : IFN-α : TYK2 (Cell-free assay): JAK1

MZ-6-55.

MZ-6-55.

BIM28011.

BIM28011.

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC 50 of 23 nMIn VitroIn the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC 50 at 0.06 μM and an estimated IC 90 at 2 μM. In MEF-3T3-myr-p110β

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC 50 of 23 nMIn VitroIn the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC 50 at 0.06 μM and an estimated IC 90 at 2 μM. In MEF-3T3-myr-p110β

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC 50 of 23 nMIn VitroIn the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC 50 at 0.06 μM and an estimated IC 90 at 2 μM. In MEF-3T3-myr-p110β

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC 50 of 23 nMIn VitroIn the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC 50 at 0.06 μM and an estimated IC 90 at 2 μM. In MEF-3T3-myr-p110β

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC 50 of 23 nMIn VitroIn the UACC-62 tumor cell line assay, SAR-260301 inhibits pAktS473 with a measured IC 50 at 0.06 μM and an estimated IC 90 at 2 μM. In MEF-3T3-myr-p110β